Zobrazeno 1 - 10
of 15
pro vyhledávání: '"JF Marin Pozo"'
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance In our country, considerable progress has been made in recent years since the establishment of the clinical therapeutic position reports (TPR) in 2013, but more research is needed about their impact on decision making. Aim a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::930053482da56660dd6a0074ca3c93d9
https://doi.org/10.1136/ejhpharm-2021-eahpconf.127
https://doi.org/10.1136/ejhpharm-2021-eahpconf.127
Autor:
E Perez Cano, Y Jimenez López, CL Muñoz Cid, N Garcia Gomez, R Claramunt García, JF Marin Pozo
Publikováno v:
Section 4: Clinical pharmacy services.
Background and importance Anti-PD-L1 immunotherapy is used to treat secondline or later non-small cell lung cancer (NSCLC). These monoclonal antibodies are the therapy of choice against NSCLC in routine clinical practice. Aim and objectives To evalua
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e3c71410b02ee95c63c0d84222393b98
https://doi.org/10.1136/ejhpharm-2021-eahpconf.103
https://doi.org/10.1136/ejhpharm-2021-eahpconf.103
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance The administration of intravenous admixtures (IVMs) in the haemato-oncology day hospital is determined by the patient‘s health status. Poor health is a cause of non-administration of IVMs, causing medication and economic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f884ae4c98e2a6f69dfcbdb6549d95a4
https://doi.org/10.1136/ejhpharm-2020-eahpconf.360
https://doi.org/10.1136/ejhpharm-2020-eahpconf.360
Autor:
JM Duarte Perez, R Claramunt García, CL Muñoz Cid, I Caba Porras, JF Marin Pozo, M Merino Almanzan
Publikováno v:
Section 4: Clinical Pharmacy Services.
Background and importance Nintedanib is indicated in combination with docetaxel for the treatment of non-small cell lung cancer (nSCLC) with adenocarcinoma histology after failure of firstline chemotherapy. Aim and objectives To evaluate the effectiv
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2ff5d9b5a97db1e7747d81711a595114
https://doi.org/10.1136/ejhpharm-2020-eahpconf.190
https://doi.org/10.1136/ejhpharm-2020-eahpconf.190
Publikováno v:
Section 5: Patient Safety and Quality assurance.
Background and importance The pharmaceutical validation of oncological prescriptions means improvement in patient safety based on quality criteria from different societies when it is carried out in a generalised, standardised and regulated way. Aim a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::846460c9b2a877ff7c40a6326b3a5fe3
https://doi.org/10.1136/ejhpharm-2020-eahpconf.359
https://doi.org/10.1136/ejhpharm-2020-eahpconf.359
Autor:
R Claramunt García, JF Marin Pozo, I Caba Porras, M Merino Almazan, AM López-López, Y Jimenez López, CL Muñoz Cid, E Perez Cano
Publikováno v:
Section 3: Production and Compounding.
Background Primary bladder neck obstruction (PBNO) is a failure in which the bladder neck does not open appropriately or completely during voiding. α-Blocker together with anticholinergics are the pharmacological therapy that has shown some benefit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::41ea499b78d81f2ed0403db3bb79a1ce
https://doi.org/10.1136/ejhpharm-2019-eahpconf.140
https://doi.org/10.1136/ejhpharm-2019-eahpconf.140
Autor:
A Sánchez Ruiz, R Claramunt García, M Merino Almazan, CL Muñoz Cid, A López López, JF Marin Pozo
Publikováno v:
Eur J Hosp Pharm
Background Pertuzumab is indicated for Her2-positive breast cancer (BC) in combination with trastuzumab and chemotherapy. Purpose To describe pertuzumab utilisation as Her2-positive BC treatment at an oncology reference hospital and to analyse treatm
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cef0e95acb3bf50fa65a1fc1bfeb4c7f
https://europepmc.org/articles/PMC7535369/
https://europepmc.org/articles/PMC7535369/
Autor:
I Caba Porras, P. Sánchez Rovira, JF Marin Pozo, A Sánchez Ruiz, M Merino Almazan, Aurelio López, JM Duarte Perez
Publikováno v:
Clinical pharmacy.
Background Bevacizumab is a very expensive antineoplastic drug that since its commercialisation has been used in an increasing number of indications. Different studies have shown a high percentage of off-label use of this drug. Purpose This work anal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8aba4faa818eaf746a6b5490fbec5099
https://doi.org/10.1136/ejhpharm-2017-000640.76
https://doi.org/10.1136/ejhpharm-2017-000640.76
Autor:
C. De La Torre Cabrera, M. Fernández Navarro, JF Marin Pozo, D. Fernández Garay, N. Cárdenas Quesada, L. Díaz Beltrán, A.L. Ortega Granados, M. Ruiz Sanjuan, P. Sanchez Rovira, M.Á. Moreno Jiménez
Publikováno v:
Journal of Thoracic Oncology. 14:S968
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2e0849a86ceef03e57eb7e3940a3716
https://doi.org/10.1016/j.jtho.2019.08.2121
https://doi.org/10.1016/j.jtho.2019.08.2121
Estudio de utilización de cetuximab en cáncer colorrectal metastásico en un hospital de tercer nivel
Publikováno v:
Farmacia Hospitalaria. 33:72-79
Objectives: In this study we will analyse the use of cetuximab in the treatment of metastatic colorectal cancer (MCC) in a third level hospital. We will establish the usage conditions in our centre in keeping with those approved in current technical
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a4497433c75f130e50ae715038c56dc2
https://doi.org/10.1016/s1130-6343(09)70991-2
https://doi.org/10.1016/s1130-6343(09)70991-2